Surprisingly, at admission only 2.8% of patients with type 2 diabetes were treated with DPP-4 inhibitors, 0.1% with GLP1-RA and 0.2% with SGLT2 inhibitors (Table 3). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.